Symptomatic, clinical and biomarker associations for mortality in hospitalized COVID-19 patients enriched for African Americans

Hassan Ashktorab 1, Antonio Pizuorno 2, Folake Adeleye 2, Adeyinka Laiyemo 2, Maryam Mehdipour Dalivand 2, Farshad Aduli 2, Zaki A Sherif 3, Gholamreza Oskrochi 4, Kibreab Angesom 2, Philip Oppong-Twene 2, Suryanarayana Reddy Challa 2, Nnaemeka Okorie 2, Esther S Moon 2, Edward Romos 2, Boubini Jones-Wonni 2, Abdoul Madjid Kone 2, Sheldon Rankine 2, Camelita Thrift 2, Derek Scholes 2, Chiamaka Ekwunazu 2, Abigail Banson 2, Brianna Mitchell 2, Guttu Maskalo 2, Jillian Ross 2, Julencia Curtis 2, Rachel Kim 2, Chandler Gilliard 2, Geeta Ahuja 2, Joseph Mathew 2, Warren Gavin 5, Areeba Kara 5, Manuel Hache-Marliere 6, Leonidas Palaiodimos 6, Vishnu R Mani 7, Aleksandr Kalabin 8, Vijay Reddy Gayam 9, Pavani Reddy Garlapati 9, Joseph Miller 10, Lakshmi Gayathri Chirumamilla 2, Fatimah Jackson 3, John M Carethers 11, Farin Kamangar 12, Hassan Brim 3

Affiliations

doi: 10.1186/s12879-022-07520-1

Abstract

Background and aims: Initial reports on US COVID-19 showed different outcomes in different races. In this study we use a diverse large cohort of hospitalized COVID-19 patients to determine predictors of mortality.

Methods: We analyzed data from hospitalized COVID-19 patients (n = 5852) between March 2020- August 2020 from 8 hospitals across the US. Demographics, comorbidities, symptoms and laboratory data were collected.

Results: The cohort contained 3,662 (61.7%) African Americans (AA), 286 (5%) American Latinx (LAT), 1,407 (23.9%), European Americans (EA), and 93 (1.5%) American Asians (AS). Survivors and non-survivors mean ages in years were 58 and 68 for AA, 58 and 77 for EA, 44 and 61 for LAT, and 51 and 63 for AS. Mortality rates for AA, LAT, EA and AS were 14.8, 7.3, 16.3 and 2.2%. Mortality increased among patients with the following characteristics: age, male gender, New York region, cardiac disease, COPD, diabetes mellitus, hypertension, history of cancer, immunosuppression, elevated lymphocytes, CRP, ferritin, D-Dimer, creatinine, troponin, and procalcitonin. Use of mechanical ventilation (p = 0.001), shortness of breath (SOB) (p < 0.01), fatigue (p = 0.04), diarrhea (p = 0.02), and increased AST (p < 0.01), significantly correlated with death in multivariate analysis. Male sex and EA and AA race/ethnicity had higher frequency of death. Diarrhea was among the most common GI symptom amongst AAs (6.8%). When adjusting for comorbidities, significant variables among the demographics of study population were age (over 45 years old), male sex, EA, and patients hospitalized in New York. When adjusting for disease severity, significant variables were age over 65 years old, male sex, EA as well as having SOB, elevated CRP and D-dimer. Glucocorticoid usage was associated with an increased risk of COVID-19 death in our cohort.

Conclusion: Among this large cohort of hospitalized COVID-19 patients enriched for African Americans, our study findings may reflect the extent of systemic organ involvement by SARS-CoV-2 and subsequent progression to multi-system organ failure. High mortality in AA in comparison with LAT is likely related to high frequency of comorbidities and older age among AA. Glucocorticoids should be used carefully considering the poor outcomes associated with it. Special focus in treating patients with elevated liver enzymes and other inflammatory biomarkers such as CRP, troponin, ferritin, procalcitonin, and D-dimer are required to prevent poor outcomes.

Keywords: African American; COVID-19; Ethnicity; Hispanic; Hospitalized; Mortality; Race; SARS CoV-2.

Conflict of interest statement

The authors declare that they have no competing interests.

Similar articles

Clinical characteristics and predictors of mortality in African-Americans with COVID-19 from an inner-city community teaching hospital in New York.

Gayam V, Chobufo MD, Merghani MA, Lamichhane S, Garlapati PR, Adler MK.J Med Virol. 2021 Feb;93(2):812-819. doi: 10.1002/jmv.26306. Epub 2020 Oct 5.PMID: 32672844 Free PMC article.

New York Inner City Hospital COVID-19 Experience and Current Data: Retrospective Analysis at the Epicenter of the American Coronavirus Outbreak.

Mani VR, Kalabin A, Valdivieso SC, Murray-Ramcharan M, Donaldson B.J Med Internet Res. 2020 Sep 18;22(9):e20548. doi: 10.2196/20548.PMID: 32540837 Free PMC article.

Higher comorbidities and early death in hospitalized African-American patients with Covid-19.

Gupta R, Agrawal R, Bukhari Z, Jabbar A, Wang D, Diks J, Alshal M, Emechebe DY, Brunicardi FC, Lazar JM, Chamberlain R, Burza A, Haseeb MA.BMC Infect Dis. 2021 Jan 18;21(1):78. doi: 10.1186/s12879-021-05782-9.PMID: 33461499 Free PMC article.

COVID-19 among African Americans and Hispanics: Does gastrointestinal symptoms impact the outcome?

Ashktorab H, Folake A, Pizuorno A, Oskrochi G, Oppong-Twene P, Tamanna N, Mehdipour Dalivand M, Umeh LN, Moon ES, Kone AM, Banson A, Federman C, Ramos E, Awoyemi EO, Wonni BJ, Otto E, Maskalo G, Velez AO, Rankine S, Thrift C, Ekwunazu C, Scholes D, Chirumamilla LG, Ibrahim ME, Mitchell B, Ross J, Curtis J, Kim R, Gilliard C, Mathew J, Laiyemo A, Kibreab A, Lee E, Sherif Z, Shokrani B, Aduli F, Brim H.World J Clin Cases. 2021 Oct 6;9(28):8374-8387. doi: 10.12998/wjcc.v9.i28.8374.PMID: 34754847 Free PMC article.

Clinical Characteristics and Morbidity Associated With Coronavirus Disease 2019 in a Series of Patients in Metropolitan Detroit.

Suleyman G, Fadel RA, Malette KM, Hammond C, Abdulla H, Entz A, Demertzis Z, Hanna Z, Failla A, Dagher C, Chaudhry Z, Vahia A, Abreu Lanfranco O, Ramesh M, Zervos MJ, Alangaden G, Miller J, Brar I.JAMA Netw Open. 2020 Jun 1;3(6):e2012270. doi: 10.1001/jamanetworkopen.2020.12270.PMID: 32543702 Free PMC article. Review.

Cited by

A two-gene marker for the two-tiered innate immune response in COVID-19 patients.

Lei H.PLoS One. 2023 Jan 17;18(1):e0280392. doi: 10.1371/journal.pone.0280392. eCollection 2023.PMID: 36649304 Free PMC article.

Cognitive dysfunction associated with COVID-19: Prognostic role of circulating biomarkers and microRNAs.

Alvarez M, Trent E, Goncalves BS, Pereira DG, Puri R, Frazier NA, Sodhi K, Pillai SS.Front Aging Neurosci. 2022 Oct 4;14:1020092. doi: 10.3389/fnagi.2022.1020092. eCollection 2022.PMID: 36268187 Free PMC article. Review.

Correction: Symptomatic, clinical and biomarker associations for mortality in hospitalized COVID-19 patients enriched for African Americans.

Ashktorab H, Pizuorno A, Adeleye F, Laiyemo A, Dalivand MM, Aduli F, Sherif ZA, Oskrochi G, Angesom K, Oppong-Twene P, Challa SR, Okorie N, Moon ES, Romos E, Jones-Wonni B, Kone AM, Rankine S, Thrift C, Scholes D, Ekwunazu C, Banson A, Mitchell B, Maskalo G, Ross J, Curtis J, Kim R, Gilliard C, Ahuja G, Mathew J, Gavin W, Kara A, Hache-Marliere M, Palaiodimos L, Mani VR, Kalabin A, Gayam VR, Garlapati PR, Miller J, Chirumamilla LG, Jackson F, Carethers JM, Kamangar F, Brim H.BMC Infect Dis. 2022 Aug 29;22(1):712. doi: 10.1186/s12879-022-07699-3.PMID: 36038841 Free PMC article. No abstract available.

KMEL References

https://pubmed.ncbi.nlm.nih.gov/

References

  1.  
    1. COVID-19 Demographic and Economic Resources. 2020. https://covid19.census.gov/. Accessed 11 Apr 2020.
  2.  
    1. Ashktorab H, et al. Racial disparity in gastrointestinal cancer risk. Gastroenterology. 2017;153(4):910–923. doi: 10.1053/j.gastro.2017.08.018. - DOI - PMC - PubMed
  3.  
    1. Zavala VA, et al. Cancer health disparities in racial/ethnic minorities in the United States. Br J Cancer. 2021;124(2):315–332. doi: 10.1038/s41416-020-01038-6. - DOI - PMC - PubMed
  4.  
    1. Ashktorab H, et al. Elevated liver enzymes, ferritin, C-reactive Protein, D-dimer, and age are predictive markers of outcomes among African American and Hispanic Patients with coronavirus disease 2019. Gastroenterology. 2021 doi: 10.1053/j.gastro.2021.03.043. - DOI - PMC - PubMed
  5.  
    1. Yancy CW. COVID-19 and african americans. JAMA. 2020;323(19):1891–1892. doi: 10.1001/jama.2020.6548. - DOI - PubMed
  6.  
    1. Carethers JM. Rectifying COVID-19 disparities with treatment and vaccination. JCI insight. 2021 doi: 10.1172/jci.insight.147800. - DOI - PMC - PubMed
  7.  
    1. Millett GA, et al. Assessing differential impacts of COVID-19 on black communities. Ann Epidemiol. 2020;47:37–44. doi: 10.1016/j.annepidem.2020.05.003. - DOI - PMC - PubMed
  8.  
    1. COVID-19 Racial Data Tracker. 2021. https://covidtracking.com/race. Accessed 7 Mar 2021.
  9.  
    1. Anaele BI, Doran C, McIntire R. Visualizing COVID-19 mortality rates and African-American populations in the USA and Pennsylvania. J Racial Ethn Health Disparities. 2021;8(6):1356–1363. doi: 10.1007/s40615-020-00897-2. - DOI - PMC - PubMed
  10.  
    1. Richardson LD, Norris M. Access to health and health care: how race and ethnicity matter. Mount Sinai J Med . 2010;77(2):166–177. doi: 10.1002/msj.20174. - DOI - PubMed
  11.  
    1. Akinyemiju T, et al. Disparities in the prevalence of comorbidities among US adults by state Medicaid expansion status. Prev Med. 2016;88:196–202. doi: 10.1016/j.ypmed.2016.04.009. - DOI - PMC - PubMed
  12.  
    1. Carethers JM. Insights into disparities observed with COVID-19. J Intern Med. 2021;289(4):463–473. doi: 10.1111/joim.13199. - DOI - PMC - PubMed
  13.  
    1. Newman LA, Winn RA, Carethers JM. Similarities in risk for COVID-19 and cancer disparities. Clin Cancer Res. 2021;27(1):24–27. doi: 10.1158/1078-0432.CCR-20-3421. - DOI - PMC - PubMed
  14.  
    1. Ashktorab H, et al. COVID-19 among African Americans and Hispanics: does gastrointestinal symptoms impact the outcome? World Journal of Clinical Cases. 2021;9(28):8374. doi: 10.12998/wjcc.v9.i28.8374. - DOI - PMC - PubMed
  15.  
    1. Palaiodimos L, et al. Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher in-hospital mortality, in a cohort of patients with COVID-19 in the Bronx, New York. Metabolism. 2020;108:154262. doi: 10.1016/j.metabol.2020.154262. - DOI - PMC - PubMed
  16.  
    1. Wiemers EE, et al. Disparities in vulnerability to complications from COVID-19 arising from disparities in preexisting conditions in the United States. Res Soc Stratif Mobil. 2020;69:100553. - PMC - PubMed
  17.  
    1. Gebhard C, et al. Impact of sex and gender on COVID-19 outcomes in Europe. Biol Sex Differ. 2020;11:1–13. doi: 10.1186/s13293-020-00304-9. - DOI - PMC - PubMed
  18.  
    1. Rentsch CT, et al. Patterns of COVID-19 testing and mortality by race and ethnicity among United States veterans: a nationwide cohort study. PLoS Med. 2020;17(9):e1003379. doi: 10.1371/journal.pmed.1003379. - DOI - PMC - PubMed
  19.  
    1. Gebhard C, et al. Impact of sex and gender on COVID-19 outcomes in Europe. Biol Sex Differ. 2020;11(1):29. doi: 10.1186/s13293-020-00304-9. - DOI - PMC - PubMed
  20.  
    1. Salje H, et al. Estimating the burden of SARS-CoV-2 in France. Science. 2020;369(6500):208–211. doi: 10.1126/science.abc3517. - DOI - PMC - PubMed
  21.  
    1. El Chaar M, King K, Galvez Lima A. Are black and Hispanic persons disproportionately affected by COVID-19 because of higher obesity rates? Surg Obes Relat Dis. 2020;16(8):1096–1099. doi: 10.1016/j.soard.2020.04.038. - DOI - PMC - PubMed
  22.  
    1. Greene DN, et al. Decreasing median age of COVID-19 cases in the United States-Changing epidemiology or changing surveillance? PLoS ONE. 2020;15(10):e0240783. doi: 10.1371/journal.pone.0240783. - DOI - PMC - PubMed
  23.  
    1. Bansal M. Cardiovascular disease and COVID-19. Diabetes Metab Syndr. 2020;14(3):247–250. doi: 10.1016/j.dsx.2020.03.013. - DOI - PMC - PubMed
  24.  
    1. Clancy P, et al. Role of the angiotensin converting enzyme 1/angiotensin II/angiotensin receptor 1 axis in interstitial collagenase expression in human carotid atheroma. Atherosclerosis. 2013;229(2):331–337. doi: 10.1016/j.atherosclerosis.2013.05.022. - DOI - PubMed
  25.  
    1. Úri K, et al. Circulating ACE2 activity correlates with cardiovascular disease development. J Renin Angiotensin Aldosterone Syst. 2016 doi: 10.1177/1470320316668435. - DOI - PMC - PubMed
  26.  
    1. Ielapi N, et al. Cardiovascular disease as a biomarker for an increased risk of COVID-19 infection and related poor prognosis. Future Med. 2020 doi: 10.2217/bmm-2020-0201. - DOI - PMC - PubMed
  27.  
    1. Zaim S, et al. COVID-19 and multiorgan response. Curr Probl Cardiol. 2020;45(8):100618. doi: 10.1016/j.cpcardiol.2020.100618. - DOI - PMC - PubMed
  28.  
    1. Peters MC, et al. COVID-19-related genes in sputum cells in asthma. Relationship to demographic features and corticosteroids. am J Respir Crit Care Med. 2020;202(1):83–90. doi: 10.1164/rccm.202003-0821OC. - DOI - PMC - PubMed
  29.  
    1. Price-Haywood EG, et al. Hospitalization and mortality among black patients and white patients with Covid-19. N Engl J Med. 2020;382(26):2534–2543. doi: 10.1056/NEJMsa2011686. - DOI - PMC - PubMed
  30.  
    1. Yehia BR, et al. Association of race with mortality among patients hospitalized with coronavirus disease 2019 (COVID-19) at 92 US hospitals. JAMA Netw Open. 2020;3(8):e2018039. doi: 10.1001/jamanetworkopen.2020.18039. - DOI - PMC - PubMed
  31.  
    1. Tomazini BM, et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial. JAMA. 2020;324(13):1307–1316. doi: 10.1001/jama.2020.17021. - DOI - PMC - PubMed
  32.  
    1. Group. R.C. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384(8):693–704. doi: 10.1056/NEJMoa2021436. - DOI - PMC - PubMed
  33.  
    1. Li Y, et al. Adverse outcomes associated with corticosteroid use in critical COVID-19: a retrospective multicenter cohort study. Front Med. 2021 doi: 10.3389/fmed.2021.604263. - DOI - PMC - PubMed
  34.  
    1. Salter A, et al. Outcomes and risk factors associated with SARS-CoV-2 Infection in a North American registry of patients with multiple sclerosis. JAMA Neurol. 2021;78(6):699–708. doi: 10.1001/jamaneurol.2021.0688. - DOI - PMC - PubMed
  35.  
    1. Lupon E, et al. Combating hypoxemia in COVID-19 patients with a natural oxygen carrier, HEMO2Life®(M101) Med Hypotheses. 2021;146:110421. doi: 10.1016/j.mehy.2020.110421. - DOI - PMC - PubMed
  36.  
    1. Abou-Ismail MY, et al. The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management. Thromb Res. 2020;194:101–115. doi: 10.1016/j.thromres.2020.06.029. - DOI - PMC - PubMed
  37.  
    1. Semeraro N, Colucci M. The prothrombotic state associated with SARS-CoV-2 infection: pathophysiological aspects. Mediterr J Hematol Infect Dis. 2021 doi: 10.4084/MJHID.2021.045. - DOI - PMC - PubMed
  38.  
    1. Bonaventura A, et al. Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. Nat Rev Immunol. 2021;21(5):319–329. doi: 10.1038/s41577-021-00536-9. - DOI - PMC - PubMed
  39.  
    1. Bzeizi K, et al. Effect of COVID-19 on liver abnormalities: a systematic review and meta-analysis. Sci Rep. 2021;11(1):10599. doi: 10.1038/s41598-021-89513-9. - DOI - PMC - PubMed

Page Navigation